Something is going on and no wonder. MSB is finally looking likely to pass muster with the FDA and CYP is ridiculously undervalued with its potential, even with a very heavy discount on time and risk involved in getting to market. If you were big Pharma, you could pick up a completely enrolled phase III trial in iPSC-derived MSC treated knee OA for dust - let alone the other applications. I was on an IPSC company in the US that traded as high at $6 billion in the US in 2021.
CYP trades for stationary expenses to some of the big Pharma and would be a steal for Sculptor alone, let alone all the other academically partnered trials. Would not be at all surprised if a takeover or something emerged.
Suspect an obligatory change in substantial holdings notice soon given the steady accumulation.
CYP Price at posting:
33.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)